Hims & Hers Health Inc. (HIMS) saw its stock plunge over 20% in after-hours trading on Monday, despite reporting better-than-expected Q4 revenue. The telehealth company's earnings met analyst estimates, but its outlook for 2025 growth fell short of expectations, sparking investor concerns.
For Q4 2024, Hims & Hers reported earnings per share of $0.11, in line with analyst consensus estimates. Revenue came in at $481.14 million, beating expectations of $470.31 million and marking a 95% year-over-year increase. The company's subscriber base grew to 2.2 million, up 45% from the previous year.
However, the company's guidance for 2025 revenue and adjusted EBITDA disappointed Wall Street. Hims & Hers expects full-year 2025 revenue of $2.3 billion to $2.4 billion, representing growth of just 16% to 22% year-over-year, compared to analyst estimates of $2.5 billion. The company also forecasted adjusted EBITDA of $270 million to $320 million, reflecting a margin of 12% to 13%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.